New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert
Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term milestones
Read more at globenewswire.comWindtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
WINDTREE THERAPEUTICS INC
NASDAQ:WINT (2/11/2025, 8:00:01 PM)
After market: 0.22 +0.06 (+37.5%)0.16
+0.02 (+13.15%)
WINT Latest News and Analysis
18 days ago - ChartmillFriday's after hours session: top gainers and losersWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
